We read with great interest the recent article by Holden et al 1 dealing with the relationship between estrogen and asymmetric dimethylarginine (ADMA) metabolism in postmenopausal women. The results of their study demonstrated that hormone replacement therapy significantly decreased plasma ADMA levels in postmenopausal women. In an in vitro study, Holden et al 1 observed that estrogen increased the activity of dimethylarginine dimethylaminohydrolase activity in endothelial cells. They proposed that estrogen can alter the catabolism and release of ADMA, which might partially contribute to the positive effect of estrogen on NO synthesis.
Response
We thank Drs Tsuda and Nishio for their interest in our paper on estradiol effects on dimethylarginine dimethylaminohydrolase (DDAH) activity and the metabolism of asymmetric dimethylarginine (ADMA). 1 We previously showed a correlation between serum ADMA concentrations and blood pressure in pregnancy, 2 a state associated with high concentrations of circulating estrogens. In the present study, we examined whether estrogen had a direct role in the regulation of ADMA metabolism. Our results both from cell culture and from women using estrogen replacement therapy demonstrated the effect of estradiol on ADMA physiology. Some of these results have been independently confirmed. 3 We were intrigued by the finding that estradiol affects erythrocyte membrane fluidity in an NO-dependent manner, attenuated by ADMA. 4 There is, to our knowledge, a single report in the literature that erythrocytes contain DDAH. 5 In our clinical study, we did not examine changes in blood pressure or cardiovascular function during estrogen therapy, whereas unfortunately Tsuda and co-workers did not measure erythrocyte DDAH activity in their study. Therefore, it is clear that only when these parameters are measured in the same study will we be in a position to comment fully on the various contributions of estrogen to ADMA/DDAH regulation and physiology in the cardiovascular system.
